1. Home
  2. KALA vs CYCN Comparison

KALA vs CYCN Comparison

Compare KALA & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.56

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Logo Cyclerion Therapeutics Inc.

CYCN

Cyclerion Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALA
CYCN
Founded
2009
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
7.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
KALA
CYCN
Price
$0.56
$1.16
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$31.50
N/A
AVG Volume (30 Days)
20.4M
43.5K
Earning Date
11-19-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,855,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1371.65
52 Week Low
$0.51
$1.20
52 Week High
$20.60
$6.25

Technical Indicators

Market Signals
Indicator
KALA
CYCN
Relative Strength Index (RSI) 37.14 28.49
Support Level $0.57 $1.43
Resistance Level $0.72 $1.51
Average True Range (ATR) 0.08 0.11
MACD 0.04 -0.03
Stochastic Oscillator 20.52 6.56

Price Performance

Historical Comparison
KALA
CYCN

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: